NCT06650163View on ClinicalTrials.gov

Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 5, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions
GliomaMalignant Brain NeoplasmMeningiomaMetastatic Malignant Neoplasm in the Brain
Interventions
PROCEDURE

Advanced Magnetic Resonance Imaging

Undergo advanced MRI

PROCEDURE

Brain Surgery

Undergo brain surgery

OTHER

Electronic Health Record Review

Ancillary studies

PROCEDURE

Immuno-Positron Emission Tomography Scan

Undergo immuno-PET

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Stereotactic Biopsy

Undergo stereotactic image-guided biopsy

DIAGNOSTIC_TEST

Zirconium Zr 89 Crefmirlimab Berdoxam

Undergo Zirconium Zr 89 Crefmirlimab Berdoxam PET

Trial Locations (1)

90095

RECRUITING

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Jonsson Comprehensive Cancer Center

OTHER